Nightstarx gene therapy may help restore vision to choroideremia patients
LONDON – Nightstarx Ltd. has been launched with £12 million (US$19.8 million) funding to commercialize a gene therapy that has been demonstrated to partly restore vision in patients losing their eyesight as a result of the X-linked inherited disorder, choroideremia.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter